Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 19/20 | 0.79 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.79 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.48 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.48 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034384 | 0.90 | LPAR1 (0.65) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4033779 | 0.90 | LPAR1 (0.65) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030296 | 0.90 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4029648 | 0.90 | LPAR1 (0.81) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4035153 | 0.89 | LPAR1 (0.76) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4031278 | 0.89 | LPAR1 (0.86) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL3841276 | 0.89 | LPAR1 (1.00) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4030950 | 0.88 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032482 | 0.88 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 | |
| SCHEMBL4032900 | 0.88 | LPAR1 (0.85) | LPAR1LPAR3LPAR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1364659-B1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-1258484-B1 | NOVEL ISOXAZOLE AND THIAZOLE COMPOUNDS AND USE THEREOF AS DRUGS | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-01-14 | — | — | EP | claimed |
| EP-1415667-B1 | PANCREATIC JUICE SECRETION REGULATORS COMPRISING LPA RECEPTOR CONTROLLER | ONO PHARMACEUTICAL CO (JP) | 2008-09-03 | — | — | EP | claimed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | LPAR1 2/4885LPAR3 4/4885LPAR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.